A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism.
D000284:Administration, Oral; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001590:Benztropine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002214:Capsules; D002746:Chlorpromazine / Q000009:adverse effects; D002986:Clinical Trials as Topic; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010919:Placebos; D012559:Schizophrenia / Q000188:drug therapy; D013997:Time Factors
D000978:Antiparkinson Agents; D002214:Capsules; D010919:Placebos; D001590:Benztropine; D000547:Amantadine; D002746:Chlorpromazine